• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Paragon 28 Inc. filed SEC Form 8-K: Other Events

    4/10/25 5:03:03 PM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email
    false0001531978NYSE00015319782025-04-102025-04-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     WASHINGTON, D.C. 20549



    FORM 8-K
      
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934
     


    Date of Report (Date of earliest event reported):  April 10, 2025
       
    Paragon 28, Inc.
     (Exact name of registrant as specified in its charter)

    Delaware
    (State or other jurisdiction
    of incorporation)
    001-40902
    (Commission
    File Number)
    27-3170186
    (IRS Employer
    Identification No.)
     
    14445 Grasslands Drive
    Englewood, Colorado 80112
    (Address of principal executive offices) (Zip Code)
     
    (720) 912-1332
    (Registrant’s telephone number, including area code)
     
    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.01 par value
     
    FNA
     
    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





    Item 8.01
    Other Events

    As previously disclosed, on January 28, 2025, Paragon 28, Inc. (“Paragon 28” or the “Company” ) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zimmer, Inc. (“Parent”), a Delaware corporation and wholly owned subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), Gazelle Merger Sub I, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary of Parent and, for certain provisions of the Merger Agreement, Zimmer Biomet. Subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent and a wholly owned indirect subsidiary of Zimmer Biomet. On March 18, 2025, the Company filed a definitive proxy statement (the “Proxy Statement”), dated March 17, 2025, with the Securities and Exchange Commission (“SEC”) in connection with the Merger.

    Since the initial filing of the Proxy Statement, two complaints have been filed in state court in New York by purported Company stockholders against the Company and the members of the Company board of directors in connection with the Merger: Jones v. Paragon 28, Inc., et al., Index No. 652025/2025 (filed Mar. 27, 2025)(N.Y. Sup. Ct.), and Smith v. Paragon 28, Inc., et al., Index No. 652037/2025 (filed Mar. 28, 2025)(N.Y. Sup. Ct.) (the “Stockholder Litigation”). The Stockholder Litigation purports to allege misrepresentation claims under New York common law relating to the Proxy Statement. Additionally, the Company has received certain demand letters (collectively, the “Demand Letters”, and together with the Stockholder Litigation, the “Litigation Matters”) from purported stockholders of the Company generally alleging that the Proxy Statement contains alleged material misstatements and omissions in violation of Section 14(a), Section 20(a) and Rule 14a-9 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). If additional demand letters are received or additional complaints are filed, absent new or different allegations that are material, the Company may choose not to announce such additional letters or filings. The plaintiffs in the Litigation Matters seek various remedies, including an order (i) enjoining the defendants from proceeding with the proposed Merger until such time that the defendants disclose certain allegedly material information that was allegedly omitted from the Proxy Statement, (ii) rescinding the proposed Merger in the event the Merger is consummated or awarding actual and putative damages to the plaintiffs in the event that it is consummated, (iii) awarding the plaintiffs fees and expenses in connection with the Litigation Matters, including reasonable attorneys’ and experts’ fees and expenses and (iv) granting such other and further relief as the court may deem just and proper.

    The Company believes that the allegations contained in the Litigation Matters are without merit and that no further disclosures are required to supplement the Proxy Statement under applicable laws. However, in order to avoid the risk of the Litigation Matters delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, the Company has determined to voluntarily make the following supplemental disclosures to the Proxy Statement, as described in this Current Report on Form 8-K. Nothing in this Current Report on Form 8-K shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, the Company specifically denies all allegations in the Litigation Matters and that any additional disclosure was or is required.

    These supplemental disclosures will not change the consideration to be paid to stockholders of the Company in connection with the Merger or the timing of the Special Meeting of Stockholders of the Company (the “Special Meeting”), which is scheduled to be held virtually, via live webcast, on April 17, 2025, at 9:00 a.m., Mountain time. The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.com/FNA2025SM. The Company board of directors continues to unanimously recommend that you vote “FOR” the proposals to be voted on at the Special Meeting as described in the Proxy Statement.

    Supplemental Disclosures and Updates to the Proxy Statement

    The following disclosures in this Current Report on Form 8-K supplement the disclosures contained in the Proxy Statement and should be read in conjunction with the disclosures contained in the Proxy Statement, which in turn should be read in its entirety. All page references are to the Proxy Statement, and terms used below, unless otherwise defined, shall have the meanings ascribed to such terms in the Proxy Statement. For clarity, new text within restated disclosures from the Proxy Statement is highlighted with bold, underlined text. 



    The disclosure in the section entitled “The Merger” under the heading “Opinion of Piper Sandler”, beginning on page 61 of the Proxy Statement is hereby amended as follows:

    The last paragraph under the heading “Opinion of Piper Sandler” on page 62 is amended as follows:

    References to (i) “LTM” historical financial information are references to (a) for each publicly traded company included in the selected public companies analysis described below under the heading “-Selected Public Companies Analysis”, the last twelve-month period for which financial information was publicly available as of January 27, 2025, based on such publicly available information, and (b) for each target company included in the selected M&A transactions described below under the heading “-Selected M&A Transactions Analysis”, the last twelve-month period for which financial information was (x) publicly available as of immediately prior to the announcement of the relevant M&A transaction, based on such publicly available information, or (y) available to Piper Sandler as of immediately prior to the announcement of the relevant M&A transaction, based on such internal non-public transaction information, and (ii) “FTM” projected financial information are references to (a) for each target company included in the selected M&A transactions analysis described below, the twelve-month period immediately following the LTM period, based on Wall Street consensus research estimates (which we refer to as the “Consensus Estimates”), disclosure by such target company or otherwise available to Piper Sandler, at the time of announcement of the relevant transaction, and (b) for the Company, the twelve-month period immediately following the LTM period, based on the Updated Company Forecasts furnished to Piper Sandler by the Company and summarized in the heading “-Certain Unaudited Financial Forecasts”. Diluted shares of Company common stock were calculated to amount to approximately 88.3 million using the treasury stock method as of January 27, 2025, the last full trading day of shares of Company common stock prior to the date on which the merger was approved by the Board, and in the case of the Company, included restricted stock units and performance stock units, and in-the-money options.

    The last paragraph on page 67 (continuing on to page 68) under the subheading “Discounted Cash Flow Analysis” is amended as follows:

    Using a discounted cash flow analysis, Piper Sandler calculated an estimated range of theoretical enterprise values for the Company based on the net present value of (i) projected unlevered after tax free cash flows from December 31, 2024, to December 31, 2034 (which included the impact of current and estimated future NOLs usage available to the Company), discounted back to December 31, 2024, and (ii) a projected terminal value at December 31, 2034, calculated using perpetuity growth rates ranging from 4.0% to 5.0%, which perpetuity growth rates were selected by Piper Sandler based on its professional judgment and resulted in a projected terminal value of $2,743 million at the midpoint of 4.5%, and discounted back to December 31, 2024. The after-tax free cash flows for each year were calculated based on the Updated Company Forecasts. Piper Sandler calculated the range of net present values as of December 31, 2024 for unlevered free cash flows for such periods, as well as the range of terminal values, based on a range of discount rates ranging from 11.0% to 13.0%, based on its estimation of the Company’s weighted average cost of capital using the capital asset pricing model, together with a size premium, in order to derive a range of implied enterprise values for the Company. Piper Sandler then derived a range of implied per share values for the Company common stock using the balance sheet data and diluted share information described above. The analysis indicated the range of implied per share values for the Company common stock was $8.91-$14.79, as compared to the $13.00 per share upfront cash consideration to be received by the holders of shares of Company common stock.

    The disclosure in the section entitled “The Merger” under the heading “Interests of the Company’s Directors and Executive Officers in the Merger”, beginning on page 77 of the Proxy Statement is hereby amended as follows:

    The table on page 82 is amended and restated by replacing such table in its entirety with the following:

    Name
     
     
    Severance
    ($)(2)(5)
     
     
    Equity Awards
    ($)(3)
     
     
    Perquisites/
    Benefits
    ($)(4)
     
     
    Tax
    Reimbursement ($)(6)
       
    Other
    ($)(7)
     
     
    Total
    ($)
    Albert DaCosta
     
     
    3,505,000
    (1) 
     
    12,496,512
     
     
    36,389
     
     
    2,752,770
       
    127,212
     
     
    18,917,883
    Chadi Chahine
     
     
    1,630,950
     
     
    9,731,302
     
     
    35,519
     
     
    2,528,706
       
    68,937
     
     
    13,995,414
    Matthew Jarboe
     
     
    600,000(1)
     
     
    4,155,998
     
     
    36,389
     
     
    __
       
    68,937
     
     
    4,861,324
    Robert McCormack
     
     
    1,048,500
     
     
    3,130,176
     
     
    35,519
     
     
    __
       
    40,327
     
     
    4,254,522
    Andrew Hill
     
     
    792,000
     
     
    1,751,890
     
     
    23,679
     
     
    __
       
    34,269
     
     
    2,601,838



    Cautionary Statement Regarding Forward-Looking Statements

    This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Paragon 28, which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements.  In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “are confident that,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “would” or the negative of these terms or other comparable terms.  Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed transaction; anticipated accretion and growth rates; plans, objectives, beliefs, expectations and intentions of the board of directors of Paragon 28 and Paragon 28 management; the financial condition, results of operations and business of Paragon 28; the possibility that the milestone associated with the contingent value rights are achieved in part or at all; and the anticipated timing of closing of the proposed transaction.

    These forward-looking statements are based on certain assumptions and analyses made by Paragon 28 in light of Paragon 28’s experience and Paragon 28’s perception of historical trends, current conditions and expected future developments, as well as other factors Paragon 28 believes are appropriate in the circumstances.  These forward-looking statements also are based on the current expectations and beliefs of the management of Paragon 28 and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Risks and uncertainties include, among other things, (i) risks related to the satisfaction of the conditions to closing the proposed transaction (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as whether the stockholders of Paragon 28 will approve the proposed transaction and the possibility that the proposed transaction does not close; (ii) risks related to the possibility that competing offers or acquisition proposals for Paragon 28 will be made; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction, including in circumstances which would require Paragon 28 to pay a termination fee; (iv) risks related to the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; (v) the risk that the businesses will not be integrated successfully; (vi) risks relating to the achievement, in part or at all, of the revenue milestone necessary for the payment of any contingent value rights; (vii) disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies, and Paragon 28’s ability to attract, motivate or retain key executives, employees and other associates; (viii) risk related to the proposed transaction diverting Paragon 28’s management’s attention from ongoing business operations; (ix) negative effects of this announcement or the consummation of the proposed transaction on the market price of Paragon 28’s common stock and on Paragon 28’s operating results; (x) the risk of litigation, including shareholder litigation, and/or regulatory actions, including any conditions, limitations or restrictions placed on approvals by any applicable governmental entities, related to the proposed transaction; and (xi) (A) other risks and uncertainties discussed in Paragon 28’s Annual Report on Form 10-K, for the fiscal year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q  (in particular, the risk factors set forth under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in such Annual Reports and Quarterly Reports), and (B) other risk factors identified from time to time in other filings with the SEC.  Filings with the SEC are available on the SEC’s website at www.sec.gov.

    The list of factors that may affect actual results and the accuracy of forward-looking statements is illustrative and is not intended to be exhaustive.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Paragon 28 undertakes no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes, expect as required by law, and expressly disclaim any obligation to revise or update any forward-looking statement to reflect future events or circumstances.


    Participants in the Solicitation

    Paragon 28 and its directors and executive officers and other members of management and employees, under SEC rules, may be deemed participants in the solicitation of proxies from the stockholders of Paragon 28 in connection with the proposed transaction. Information regarding Paragon 28’s directors and executive officers can be found in Paragon 28’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 5, 2024 and subsequent statements of beneficial ownership on file with the SEC. These documents are available free of charge at the SEC’s web site at www.sec.gov and on Paragon 28’s website at www.paragon28.com.  Additional information regarding the interests of Paragon 28’s participants in the solicitation of Paragon 28’s stockholders, which may, in some cases, be different than those of Paragon 28’s stockholders generally, is included in Paragon 28’s definitive proxy statement relating to the proposed transaction, dated March 17, 2025, which was filed with the SEC on March 18, 2025.

    Additional Information and Where to Find It

    In connection with the proposed transaction, on March 18, 2025, Paragon 28 filed a definitive proxy statement, dated March 17, 2025, with the SEC.  The definitive proxy statement was mailed to Paragon 28’s stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF PARAGON 28 ARE URGED TO READ THE PROXY STATEMENT AND ALL RELEVANT DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (if and when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov, and on Paragon 28’s website at www.paragon28.com. In addition, the proxy statement and other documents may be obtained free of charge by directing a request to Paragon 28, Inc., Robert McCormack, 14445 Grasslands Drive, Englewood, Colorado, telephone: (720) 912-1332.
     



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


     
    PARAGON 28, INC.
       

    By:
    /s/ Robert S. McCormack
     
       
    Name:
    Robert S. McCormack
     
       
    Title:
    General Counsel and Corporate Secretary
     
    Date: April 10, 2025
    Get the next $FNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Paragon 28 downgraded by Needham

      Needham downgraded Paragon 28 from Buy to Hold

      1/29/25 2:02:26 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 downgraded by William Blair

      William Blair downgraded Paragon 28 from Outperform to Mkt Perform

      1/29/25 7:36:30 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • William Blair initiated coverage on Paragon 28

      William Blair initiated coverage of Paragon 28 with a rating of Outperform

      9/29/23 7:20:32 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Paragon 28 Inc.

      SC 13G - Paragon 28, Inc. (0001531978) (Subject)

      8/9/24 9:02:32 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/14/24 3:29:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/13/24 4:23:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

      3/24/25 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

      3/11/25 4:01:00 PM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

      3/7/25 4:32:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

      2/6/25 6:30:00 AM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

      11/12/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

      Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

      10/17/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:24:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:23:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:22:43 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:07 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:10 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:14 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      3/18/24 5:34:02 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      11/13/23 8:00:07 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Appointment of Stephen M. Deitsch as new Chief Financial Officer

      OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

      4/4/24 11:43:23 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

      3/28/22 4:02:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care